Antiseizure therapy in focal-onset epilepsy according to the approved local indication.
Brivaracetam has high affinity for synaptic vesicle protein SV2A.
The therapeutic objective is seizure control; response and tolerability are individual.
Choice of antiseizure therapy depends on seizure type, comorbidity, interactions and reproductive considerations.
Composition & dosage
Composition: Brivaracetam · 50 mg
Dosage form: Tablet
Dosage: As prescribed by the doctor.
How it works
High-affinity binding to synaptic vesicle protein 2A (SV2A); the exact anticonvulsant mechanism is not fully established.
High-affinity binding to synaptic vesicle protein 2A (SV2A)
the exact anticonvulsant mechanism is not fully established.
Phase III randomized trials and meta-analytic evidence support adjunctive brivaracetam for focal-onset seizures, with responder and seizure-frequency benefits versus placebo.
Safety information
Somnolence, dizziness and fatigue may occur.
Monitor for behavioural or psychiatric symptoms and suicidality as with antiseizure medicines.
Do not change or stop antiseizure therapy abruptly without clinical supervision.
Review the current approved prescribing information, contraindications, interactions, organ-function considerations, pregnancy/lactation advice and patient-specific risks before prescribing.
Evidence context
Phase III randomized trials and meta-analytic evidence support adjunctive brivaracetam for focal-onset seizures, with responder and seizure-frequency benefits versus placebo.
Efficacy varies by patient and background therapy; the evidence is for brivaracetam, not specifically for the Zaiva brand.